Association of microRNA-21 expression with breast cancer subtypes and its potential as an early biomarker

Breast cancer has become the most diagnosed cancer worldwide in 2020 with high morbidity and mortality rates. The alarming increase in breast cancer incidence has sprung many researchers to focus on developing novel screening tests to identify early breast cancer which will allow clinicians to provi...

Full description

Saved in:
Bibliographic Details
Published inPathology, research and practice Vol. 254; p. 155073
Main Authors Lee, Sau Har, Brianna
Format Journal Article
LanguageEnglish
Published Germany Elsevier GmbH 01.02.2024
Subjects
Biomarker
Biomarkers, Tumor - genetics
Breast cancer
Breast Neoplasms - diagnosis
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Cancer diagnostics
Female
Gene Expression Regulation, Neoplastic
Humans
MicroRNAs - metabolism
MiR-21 overexpression
MiRNA testing
Biomarker
Breast cancer
Cancer diagnostics
MiRNA testing
MiR-21 overexpression
Online AccessGet full text

Cover

More Information
Summary:Breast cancer has become the most diagnosed cancer worldwide in 2020 with high morbidity and mortality rates. The alarming increase in breast cancer incidence has sprung many researchers to focus on developing novel screening tests to identify early breast cancer which will allow clinicians to provide timely and effective treatments. With much evidence supporting the notion that the deregulation of miRNAs (a class of non-coding RNA) greatly contributes to cancer initiation and progression, the promising role of miRNAs as cancer biomarkers is gaining traction in the research world. Among the upregulated miRNAs identified in breast carcinogenesis, miR-21 was shown to be significantly expressed in breast cancer tissues and bodily fluids of breast cancer patients. Therein, this review paper aims to provide an overview of breast cancer, the role and significance of miR-21 in breast cancer pathogenesis, and its potential as a breast cancer biomarker. The paper also discusses the current types of tumor biomarkers and their limitations, the presence of miR-21 in extracellular vesicles and plasma, screening methods available for miRNA detection along with some challenges faced in developing diagnostic miR-21 testing for breast cancer to provide readers with a comprehensive outlook based on using miR-21 in clinical settings.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0344-0338
1618-0631
DOI:10.1016/j.prp.2023.155073